Former Sen. Hatch: Drug Negotiation Deal Undermines Drug Patent Law

By John Wilkerson / November 18, 2021 at 2:19 PM
Former Utah GOP senator Orrin Hatch, for whom Hatch-Waxman drug patent law is named, says the negotiation timeline in Democrats’ drug-pricing deal would undermine the long-standing patent law, echoing industry concerns the deal would kill the generic and biosimilar industries that he helped create. “The bill would seem to impose a new price regulation scheme that would undermine the generic competition that is at the heart of Hatch-Waxman,” according to an Orrin G. Hatch Foundation statement . “Likewise, it could...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.